% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Landry:300254,
      author       = {A. P. Landry and J. Z. Wang and V. Patil and J. Liu and C.
                      Gui and Y. Ellenbogen and A. Ajisebutu and L. Yefet and Q.
                      Wei and O. Singh and J. Sosa and S. Mansouri and A. A.
                      Cohen-Gadol and G. Tabatabai$^*$ and M. Tatagiba and F.
                      Behling and J. S. Barnholtz-Sloan and A. E. Sloan and S.
                      Chotai and L. B. Chambless and A. Mansouri and S. Makarenko
                      and S. Yip and F. Ehret and D. Capper$^*$ and D. S. Tsang
                      and J. Moliterno and M. Gunel and P. Wesseling and F.
                      Sahm$^*$ and K. Aldape and A. Gao and G. Zadeh and F.
                      Nassiri},
      title        = {{C}hromosome 1p {L}oss and 1q {G}ain for {G}rading of
                      {M}eningioma.},
      journal      = {JAMA oncology},
      volume       = {11},
      number       = {6},
      issn         = {2374-2437},
      address      = {Chicago, Ill.},
      publisher    = {American Medical Association},
      reportid     = {DKFZ-2025-00715},
      pages        = {644-649},
      year         = {2025},
      note         = {2025 Jun 1;11(6):644-649},
      abstract     = {The World Health Organization (WHO) classification of
                      central nervous system tumors (CNS) grading for meningioma
                      was updated in 2021 to include rare molecular features,
                      namely homozygous deletions of CDKN2A or CDKN2B and TERT
                      promotor alterations. Previous work, including the
                      cIMPACT-NOW statement, has discussed the potential value of
                      including chromosomal copy number alterations to help refine
                      the current grading system.To identify chromosomal copy
                      number alterations that could be used to improve the current
                      CNS WHO grading of meningioma.In this cohort study, patients
                      with surgically treated meningioma were followed-up until
                      recurrence or progression of disease or death. Chromosomal
                      copy number alterations were then correlated with
                      progression-free survival (PFS) to identify new outcome
                      biomarkers. This study included patients with a
                      histopathological diagnosis of meningioma from multiple
                      institutions in Canada, the US, and Germany, with molecular
                      data collection starting in 2016. Data were analyzed from
                      January to September 2024.All patients underwent surgery for
                      meningioma and a subset underwent radiation therapy.The main
                      outcome was PFS. Cox regression analysis was used to
                      identify copy number alterations associated with outcomes in
                      the context of WHO grading.Among 1964 patients with
                      meningioma (1256 female; median [IQR] age, 58 [48-69] years)
                      assessed, loss of chromosome 1p in WHO grade 1 meningiomas
                      was associated with significantly worse outcomes compared
                      with tumors without loss of 1p (median PFS, 5.83 $[95\%$ CI,
                      4.36-∞] years vs 34.54 $[95\%$ CI, 16.01-∞] years;
                      log-rank P < .001). Outcomes of patients with WHO grade 1
                      tumors with loss of chromosome 1p were comparable to those
                      of patients with WHO grade 2 tumors (median PFS, 4.48
                      $[95\%$ CI, 4.09-5.18] years). Combined loss of chromosome
                      1p and gain of chromosome 1q were associated with outcomes
                      that were highly concordant with WHO grade 3 tumors,
                      regardless of initial grade (median PFS: grade 1, 2.23
                      $[95\%$ CI, 1.28-∞] years; grade 2, 1.90 $[95\%$ CI,
                      1.23-2.25] years; grade 3, 2.27 $[95\%$ CI, 1.68-3.05]
                      years).These findings highlight a role for cytogenetic
                      profiling in the next iteration of CNS WHO grading, with a
                      specific focus on chromosome 1p loss and 1q gain, suggesting
                      that chromosome 1p loss, in addition to 22q loss, should be
                      added as a criterion for a CNS WHO grade of 2 and addition
                      of 1q gain as a criterion for a CNS WHO grade of 3.},
      cin          = {TU01 / BE01 / B300},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331 / I:(DE-He78)BE01-20160331 /
                      I:(DE-He78)B300-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40178835},
      doi          = {DOI:10.1001/jamaoncol.2025.0329},
      url          = {https://inrepo02.dkfz.de/record/300254},
}